AzTrials
AzTrials

SchizophreniaNCT01945333

Personalized and Scalable Cognitive Remediation Approaches

A study testing Cognitive remediation in people with Schizophrenia and Schizoaffective Disorder, run by New York State Psychiatric Institute at 5 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to develop and pilot test personalized and scalable approaches to Cognitive Remediation (CR) for schizophrenia and schizoaffective disorder. The intent is to more clearly define the therapeutic targets important to the facilitation of cognitive and functional improvement so that clinicians… Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Schizophrenia, Schizoaffective Disorder
What is being tested?
Cognitive remediation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
115 participants
Where
5 sitesUnited States
Study dates
Sep 2013to 20 Mar 2019
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnostic and Statistical Manual-IV (DSM-IV) diagnosis of schizophrenia or schizoaffective disorder
  • Age 18 to 65
  • English speaking
  • Psychiatrically stable, verified by current living/treatment status

Who cannot join

  • Indication of mental retardation, determined by estimated IQ of less than 70
  • Hearing or visual impairment that precludes completing assessments
  • Neurologic illness that may affect brain physiology (e.g. Parkinson's, seizure disorder, epilepsy)
  • Current substance dependence symptoms in the past 6 weeks
  • Participation in cognitive remediation in the 12 months prior to study entry.

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

United States5 sites
  • Williamsburg Clinic

    Brooklyn, New York, 11206

  • Institute for Community Living

    Brooklyn, New York, 11207

  • Nyspi/ Cumc

    New York, New York, 10032

  • The Bridge Inc

    New York, New York, 10040

  • FEGS Bronx Mental Health Clinic

    The Bronx, New York, 10467

Other trials in United States

About this study

The purpose of this study is to develop and pilot test personalized and scalable approaches to Cognitive Remediation (CR) for schizophrenia and schizoaffective disorder. The intent is to more clearly define the therapeutic targets important to the facilitation of cognitive and functional improvement so that clinicians know how to customize cognitive interventions and deliver treatment in a more effective, efficient and personally relevant manner.

Read the detailed description

There are three phases of this study.

Phase 1: Development and Adaptation. The goal of this phase is to adapt currently used computer based CR approaches to make them more personalized and scalable. We will create two CR interventions which differ in choice and pacing of the cognitive exercises. This phase is complete.

Phase 2: Open Trial and Intervention Refinement. The goal of this phase is to obtain quantitative and qualitative feedback on the acceptability and usability of the interventions from participants to inform further refinement of the assessment and treatment packages. We will recruit ten subjects from an outpatient psychiatric rehabilitation program in New York City. After determining study eligibility, individuals will complete a standardized neuropsychological battery for schizophrenia assessment, and a 5-minute Tone Matching Test to assess basic auditory processing. Participants will be randomly assigned to receive one of two intervention packages, developed in Phase 1. Each session includes 60 minutes of computer-based learning activities and a 15 minute therapist-led discussion that links the computer activities to cognition as applied to daily tasks and recovery goals. Participants will complete a total of 10 sessions attending 2-3 times weekly for 5 weeks. During each session, participants will be asked to keep a log of software used. At the conclusion of this abbreviated trial, the participants will participate in focus groups in which they will be asked to provide verbal feedback on how enjoyable, engaging, and useful they perceived the computer and discussion based exercises to be. Participants will be asked to provide verbal feedback on the assessment procedures. CR clinicians will join the research team to discuss participants' engagement and their experience with administering the Tone Matching Test and interventions. Qualitative data summarized from participant logs and focus groups will be considered by the research team to refine the assessment battery, treatment parameters, and rubric of learning exercises. This phase is complete.

Phase 3: Pilot Feasibility Trial. People with a diagnosis of schizophrenia or schizoaffective disorder may be referred by their treating clinician or may respond to posted advertisements to inquire about study participation. After being informed of study procedures, interested individuals will be asked to sign a consent form that documents willingness to participate in this study. Following informed consent, participants will be asked questions about demographic characteristics (e.g. age, education, employment), medication and psychosocial treatment status, psychiatric symptoms and symptoms severity, and will complete a brief assessment of estimated Intelligence. Those with an Intelligence Quotient (IQ) estimate below 70 or meeting substance dependence criteria at the time of evaluation will be exited from the study. In the same or second assessment session, participants will complete assessments of neuropsychological ability, current functioning, and motivation for treatment. Participants will then be randomly assigned to one of two treatment conditions named "Brain Basics" or "Brain Exercises".

Each treatment condition is structured in a group format of up to 5 participants. Both treatments use commercially available computer-based training software to exercise cognitive skills such as speed of processing, attention, working memory, and verbal memory. Both conditions will entail 50 minutes on the computer and 10 minutes group discussion. In the discussion, participants review the cognitive activities they are working on and how they will help them achieve their recovery goals. The treatment phase will consist of 30 separate sessions each 60 minutes in duration, administered 3 times a week over the course of a 10-week period. Participants will be re-tested on outcome measures approximately 1 week following end of treatment, and again 3 months later.

Being tested
Cognitive remediation
Keywords
Cognitive remediation, Schizophrenia, Schizoaffective disorder
Medical subject headings
Schizophrenia, Psychotic Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cognitive remediationBehavioural

    Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.

Study groups in NCT01945333
Study groupRoleWhat they receive
Brain Basics for Impaired Tone MatchersActive comparatorCognitive remediation includes sensory processing training
Receives: Behavioral: Cognitive remediation
Brain Basics for Intact Tone MatchersActive comparatorCognitive remediation includes sensory processing training
Receives: Behavioral: Cognitive remediation
Brain Training for Impaired Tone MatcherActive comparatorCognitive remediation does not include sensory processing training
Receives: Behavioral: Cognitive remediation
Brain Training for Intact Tone MatchersActive comparatorCognitive remediation does not include sensory processing training
Receives: Behavioral: Cognitive remediation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Feasibility of Enrollment, Randomization and Retention

    Feasibility is measured by enrollment, acceptability of randomization defined as number initiated allocated treatment, retention of subjects defined as number completed allocated treatment

    Measured: Two years

Secondary outcomes (2)
  1. Change in Neurocognition From Baseline to Treatment End-point

    Change in neurocognition is calculated as the difference in the MATRICS Consensus Cognitive Battery Neurocognitive Composite Score between baseline and treatment end-point (10 weeks). The MATRICS Consensus Cognitive Battery Neurocognitive Composite T-Score is a scaled score calculated from the following component subscales: a) working memory; b) attention/vigilance; c) verbal learning; d) visual learning; e) processing speed; f) reasoning and problem solving. The mean T-score is 50 with a standard deviation of 10. Higher scores on the scale mean better outcomes. Higher change scores mean better outcomes.

    Measured: 10 weeks

  2. Change in Neurocognition From Baseline to 3-month Follow-up

    Change in neurocognition is calculated as the difference in the MATRICS Consensus Cognitive Battery Neurocognitive Composite Score between baseline and 3-month follow-up (5.5 to 6 months). The MATRICS Consensus Cognitive Battery Neurocognitive Composite T-Score is a scaled score calculated from the following component subscales: a) working memory; b) attention/vigilance; c) verbal learning; d) visual learning; e) processing speed; f) reasoning and problem solving. The mean T-score is 50 with a standard deviation of 10. Higher scores on the scale mean better outcomes. Higher change scores mean better outcomes.

    Measured: 5.5 to 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Sep 2013 (estimated)
  2. Study startSep 2013
  3. Primary completion2 Oct 2017
  4. Study completion20 Mar 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
115 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01945333
Sponsor's protocol ID
#6721
Other IDs
1R34MH100317-01
Status last verified
Jun 2026
First submitted
13 Sep 2013
Last updated
17 Jul 2026
Data monitoring committee
No
Individual data sharing
No: This trial started enrolling participants before January 1, 2019.

Publications

  • Medalia A, Saperstein AM, Qian M, Javitt DC. Impact of baseline early auditory processing on response to cognitive remediation for schizophrenia. Schizophr Res. 2019 Jun;208:397-405. doi: 10.1016/j.schres.2019.01.012. Epub 2019 Jan 18.

    PubMed 30665714

Questions about this trial

What is this clinical trial studying?

A study testing Cognitive remediation in people with Schizophrenia and Schizoaffective Disorder, run by New York State Psychiatric Institute at 5 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Jul 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Feasibility of Enrollment, Randomization and Retention (time frame: Two years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01945333, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in